- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07770178
Safety, Tolerability, and Accuracy of a Hydrogel-Based Wearable Dynamic Intraocular Pressure Sensor in Healthy Adults
Safety, Tolerability, and Accuracy of a Novel Hydrogel-Based Wearable Dynamic Intraocular Pressure Sensor in Healthy Adults: A Single-Center, Single-Arm Exploratory Clinical Trial
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Peiyao Jin
- Номер телефона: +8613564534911
- Электронная почта: peiyaojin@hotmail.com
Места учебы
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200080
- Shanghai General Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- Voluntarily agrees to participate in the study and provides written informed consent.
- Has previously worn contact lenses.
- Has no ocular disease other than refractive error.
- Central corneal thickness between 540 and 560 μm, inclusive.
- Corneal curvature between 42 and 44 D, inclusive.
Exclusion Criteria:
- Unable to tolerate the hydrogel-based wearable dynamic intraocular pressure sensor.
- Pregnant or breastfeeding.
- History of allergy to relevant medical materials or known hypersensitivity to materials used in the investigational device.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Другой
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Hydrogel-Based Wearable Dynamic Intraocular Pressure Sensor
Participants will undergo a single-arm evaluation of a hydrogel-based wearable dynamic intraocular pressure sensor (CLS). After 2 hours of fasting from food and water, baseline ocular safety examinations will be performed. Intraocular pressure will first be measured using non-contact tonometry (NCT) and Goldmann applanation tonometry (GAT). Participants will then wear the CLS and undergo a 10-minute adaptation period before the first sensor signal is recorded. Participants will drink 1 L of water within 5 minutes. At 10-15 minutes after completion of water intake, a second sensor signal will be recorded, followed by CLS removal and repeat GAT and NCT measurements. After an interval of at least 45 minutes, NCT and GAT will be repeated, the CLS will be worn again for a 10-minute adaptation period, and a third sensor signal will be recorded. After completion of the measurement procedure, the CLS will be removed and ocular safety examinations will be repeated to evaluate changes associate |
The investigational device is a wearable hydrogel-based contact lens sensor designed to record electrical signals associated with changes in intraocular pressure.
The CLS is worn on the study eye and allowed to stabilize for 10 minutes before signal acquisition.
Sensor signals are obtained at three predefined measurement points and compared with Goldmann applanation tonometry measurements to assess measurement accuracy.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Absolute Error of CLS-Predicted Intraocular Pressure Compared With Goldmann Applanation Tonometry
Временное ограничение: Day 1, at the third validation measurement
|
The first two paired measurements of the contact lens sensor (CLS) signal and Goldmann applanation tonometry (GAT) intraocular pressure will be used to establish an individualized linear calibration equation for each participant.
The third CLS signal will be converted to a predicted intraocular pressure using the individualized calibration equation.
Absolute error is defined as the absolute difference between the CLS-predicted intraocular pressure and the corresponding GAT measurement, expressed in mmHg.
|
Day 1, at the third validation measurement
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Agreement Between CLS-Predicted Intraocular Pressure and Non-Contact Tonometry
Временное ограничение: Day 1, at the third validation measurement
|
At the third validation assessment, intraocular pressure predicted from the contact lens sensor (CLS) using the individualized calibration equation will be compared with the corresponding non-contact tonometry (NCT) measurement.
|
Day 1, at the third validation measurement
|
|
Increased incidence of corneal fluorescent staining grade
Временное ограничение: Baseline and at the post-study ocular examination on Day 1
|
Corneal fluorescence staining grading (National Eye Institute (NEI) standards) The cornea is divided into five regions (central, top, and above).Square, inferior, nasal side, temporal side), each area scores 0-3 points (0 = unstained, 1 = sparse dots, 2 = dense dots, 3 = fused or patchy)
|
Baseline and at the post-study ocular examination on Day 1
|
|
Conjunctival congestion score
Временное ограничение: Baseline and at the post-study ocular examination on Day 1
|
The Ora Calibra® scale was used to measure conjunctival redness in each eye.
Each eye will be rated on a scale from 0 to 4, with 0 being best and 4 being the worst.
|
Baseline and at the post-study ocular examination on Day 1
|
|
Change From Baseline in Tear Break-Up Time After CLS Wear
Временное ограничение: Baseline and at the post-study ocular examination on Day 1
|
Tear break-up time (TBUT) will be measured before and after CLS wear.
After blinking several times, the participant will keep the eye open while looking straight ahead, and the time until the first dry spot appears in the tear film will be recorded in seconds.
|
Baseline and at the post-study ocular examination on Day 1
|
|
Change From Baseline in Best-Corrected Visual Acuity After CLS Wear
Временное ограничение: Baseline and at the post-study ocular examination on Day 1
|
Best-corrected visual acuity (BCVA) will be assessed before and after CLS wear.
Change from baseline will be calculated by comparing the post-study BCVA with the baseline BCVA.
|
Baseline and at the post-study ocular examination on Day 1
|
|
CLDEQ-8-Based Immediate Ocular Tolerability Questionnaire
Временное ограничение: Immediately after completion of CLS wear on Day 1
|
Immediate ocular tolerability during wear of the investigational contact lens sensor (CLS) will be assessed using a study-specific questionnaire adapted from the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8). The questionnaire contains eight items assessing: frequency and intensity of ocular discomfort, frequency and intensity of ocular dryness, frequency and intensity of fluctuating or blurred vision, frequency of wanting to close the eye because of discomfort, and the desire to remove the CLS because of discomfort. Frequency items are scored from 0 to 4, intensity items from 0 to 5, and the item assessing the desire to remove the CLS from 1 to 6. Higher scores indicate worse ocular tolerability. |
Immediately after completion of CLS wear on Day 1
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- 20260424074539870
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .